{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":4,"sponsored":0,"items":[{"id":"n_7edesd6atalvrslrtzvq","seq":1459232,"kind":"article","title":"Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026","url":"https://www.prnewswire.com/news-releases/antengene-to-present-latest-preclinical-results-of-novel-cos-tce-platform-in-rapid-oral-abstract-presentation-at-sitc-2026-302891249.html","published":"2026-10-03T01:28:11Z","seen":"2026-10-03T01:28:11Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","health","business","politics"],"authors":["Antengene Corporation Limited"],"entities":[{"id":"Q16900986","name":"Swinomish Indian Tribal Community","type":"event"}],"story":"st_7edesd6atalvrslrtzvq","category":"science-technology","category_p":0.55,"sentiment":"neutral","tone":-0.08,"political":0.08},{"id":"n_wfrfqvlszvyv7pymvzsq","seq":1348135,"kind":"press_release","title":"MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026","url":"https://www.globenewswire.com/news-release/2026/10/02/3373825/0/en/mink-therapeutics-to-present-data-on-treatment-resistant-colorectal-cancer-and-clearance-of-senescent-tumor-cells-and-fibroblasts-at-sitc-2026.html","summary":"NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in…","published":"2026-10-02T13:00:00Z","seen":"2026-10-02T13:07:57Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:inkt","us6036931029"],"entities":[{"id":"Q16900986","name":"Swinomish Indian Tribal Community","type":"event"}],"mentions":2,"story":"st_wfrfqvlszvyv7pymvzsq","category":"health","category_p":0.46,"sentiment":"neutral","tone":0.14,"political":0.18},{"id":"n_w6tcc6byzv22i2uwslba","seq":1348133,"kind":"press_release","title":"Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)","url":"https://www.globenewswire.com/news-release/2026/10/02/3373822/0/en/immuneering-to-present-at-the-41st-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc.html","published":"2026-10-02T13:00:00Z","seen":"2026-10-02T13:07:57Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:imrx","us45254e1073"],"entities":[{"id":"Q6053320","name":"Society for Immunotherapy of Cancer","type":"org"},{"id":"Q16900986","name":"Swinomish Indian Tribal Community","type":"event"}],"mentions":2,"story":"st_w6tcc6byzv22i2uwslba","category":"health","category_p":0.63,"sentiment":"positive","tone":0.52,"political":0.11},{"id":"n_vm462doedwsw5baludka","seq":1348132,"kind":"press_release","title":"Candel Therapeutics to Present at the SITC 2026 Annual Meeting","url":"https://www.globenewswire.com/news-release/2026/10/02/3373820/0/en/candel-therapeutics-to-present-at-the-sitc-2026-annual-meeting.html","summary":"NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI)…","published":"2026-10-02T13:00:00Z","seen":"2026-10-02T13:07:57Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nasdaq:cadl","us1374041093"],"entities":[{"id":"Q30283508","name":"Candel Therapeutics","type":"org"},{"id":"Q16900986","name":"Swinomish Indian Tribal Community","type":"event"}],"mentions":2,"story":"st_vm462doedwsw5baludka","category":"economy-business","category_p":0.31,"category2":"health","sentiment":"neutral","tone":0.37,"political":0.08}]}